Search clinical trials for: 10-1074

Total 3434 results

International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Rockefeller University
University of Cologne

Completed

A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074

Healthy | HIV

Germany, United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa (ACACIA)

HIV-1-infection
National Institute of Allergy and Infectious Diseases...

Completed

Dual bNAb Treatment in Children

HIV Infection

Botswana
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Pausing Antiretroviral Treatment Under Structured Evaluation (PAUSE)

HIV-1-infection

Malawi, South Africa, Botswana
National Institute of Allergy and Infectious Diseases...

Terminated

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

HIV

United States
National Institute of Allergy and Infectious Diseases...
Rockefeller University

Withdrawn

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
ImmunityBio, Inc.; Rockefeller University

Recruiting

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

HIV-1

United States
Rockefeller University

Completed

3BNC117 and 10-1074 in HIV Uninfected Adults

Human Immunodeficiency Virus

United States
Imperial College London
Bill and Melinda Gates Foundation; University of Oxford; Rockefeller University

Recruiting

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs). (RIO)

HIV/AIDS and Infections

Denmark, United Kingdom
University of Aarhus
Odense University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

HIV-1-infection

Norway, Denmark, United States, Australia
National Institute of Allergy and Infectious Diseases...

Terminated

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

HIV

United States
Naurex, Inc, an affiliate of Allergan plc

Completed

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers (NRX-1074)

Major Depressive Disorder

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

HIV-1 Infection

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
Rockefeller University

Completed

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Human Immunodeficiency Virus

United States
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Human Immunodeficiency Virus

United States
Curacle Co., Ltd.
KCRN Research, LLC

Completed

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Diabetic Macular Edema

United States
ANRS, Emerging Infectious Diseases
Institut Pasteur; Rockefeller University

Recruiting

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control (RHIVIERA-02)

HIV/AIDS and Infections

France
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

Psoriasis

China
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

3BNC117 and 10-1074 in ART-treated Individuals

Human Immunodeficiency Virus

United States
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
KBP Biosciences
Covance

Completed

Mass Balance Study of KBP-5074 in Healthy Male Subjects

Healthy

United States
KBP Biosciences

Completed

Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074

Healthy
Avidity Biosciences, Inc.

Enrolling by invitation

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping (EXPLORE44OLE)

Duchenne Muscular Dystrophy | DMD | Exon 44 | Duchenne

United States
Synvista Therapeutics, Inc

Completed

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

Coronary Artery Disease | Diabetes

United States
Rockefeller University
University Hospital of Cologne

Completed

3BNC117 and 10-1074 in HIV-infected Individuals

Human Immunodeficiency Virus (HIV)

United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
KBP Biosciences
Covance

Completed

Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment

Healthy | Moderate Hepatic Impairment

United States
KBP Biosciences
Worldwide Clinical Trials

Completed

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease (BLOCKCKD)

Hypertension | Chronic Kidney Diseases

United States
NorthSea Therapeutics B.V.

Completed

A Phase 1, First Time in Humans Study of NST-1024

Hypertriglyceridemia

United Kingdom
Elixiron Immunotherapeutics Inc.
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

Healthy Volunteers

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Healthy | Renal Impairment

United States
Invicro

Completed

Assessment of [18F]MNI-1054 as a Marker for LSD1

Healthy Volunteers (HV)

United States
Catabasis Pharmaceuticals

Completed

A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
NYU Langone Health
Naurex, Inc, an affiliate of Allergan plc

Withdrawn

NRX-1074 in Early Course Schizophrenia

Schizophrenia

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Healthy

United States
Invicro

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-1054

Healthy Volunteers

United States
Curacle Co., Ltd.
Théa Open Innovation, France

Active, not recruiting

The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States, Puerto Rico
GlycoMimetics Incorporated

Completed

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Sickle Cell Disease

United States
Merck Sharp & Dohme LLC

Completed

Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)

Hepatitis C
Avidity Biosciences, Inc.

Recruiting

Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping (EXPLORE44)

Duchenne Muscular Dystrophy | Exon 44

United States
Mylan Specialty, LP

Completed

Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

Pain | Acute Pain | Post Operative Pain

United States
Catabasis Pharmaceuticals

Terminated

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (GalaxyDMD)

Duchenne Muscular Dystrophy

United States, Canada, Australia, United Kingdom, Germany, Sweden
Molecular Insight Pharmaceuticals, Inc.
National Cancer Institute (NCI)

Withdrawn

A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy

Prostate Cancer

United States

Search clinical trials for: 10-1074

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations